Characterization of human immunodeficiency virus drug-resistance mutations among individuals with low-level-viremia in low-income and middle-income countries: A meta-analysis
Most individuals with LLV have resistance mutations and remain on a failed regimen over an extended period. Because resistance testing is not routinely performed in LMIC, lowering the viral failure threshold may improve timely switching to effective regimens, preserve treatment options, and reduce resistance accumulation in high HIV burden regions.
Authors
- Jackline Vicent Mbishi
- Habib O. Ramadhani (ORCID: https://orcid.org/0000-0001-9372-9359)
- Ibrahim Ahmed El-Imam (ORCID: https://orcid.org/0009-0006-3191-8051)
- Timothy Antipas Peter (ORCID: https://orcid.org/0000-0002-3112-1847)
- Hafidha Mhando Bakari (ORCID: https://orcid.org/0009-0009-8937-8205)
- Mariam Salim Mbwana (ORCID: https://orcid.org/0009-0008-2330-6834)
- Hassan Fredrick Fussi
- Beatrice Kelvin Mpimo
- Upendo Kayeke Chenya
- Sanad Wael Dababneh
- Nicaise Ndembi
- Haji Mbwana Ally
Institutions
- University of Jordan (JO)
- University of Maryland, Baltimore (US)
- International Vaccine Institute (KR)
- Drug Enforcement Administration (US)
- Muhimbili University of Health and Allied Sciences (TZ)
- University of Dar es Salaam (TZ)
- Aga Khan Hospital Dar es Salaam (TZ)
- Lincoln University - California (US)
- Institute of Human Virology (NG)
- Kilimanjaro Christian Medical Centre (TZ)
- Primary Health Care Institute (TZ)
Publication Details
- Journal
- World Journal of Virology
- Published
- 2026-03-13
- DOI
- https://doi.org/10.5501/wjv.v15.i1.114375
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00